Choroidal melanoma is a rare, vision- and life-threatening ocular cancer

There are no approved drug therapies for the first line treatment of choroidal melanoma and the current standard of care using radiotherapy leaves many patients with major vision loss, potential disfiguration, and a wide range of comorbidities. Despite the current treatments with radiotherapy, the long-term prognosis is poor with death occurring in more than 50% cases.

New options for early treatment intervention that preserve vision are urgently needed.